4 results
Primary Objective: To determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective: To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.To assess…
Primary ObjectiveTo determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective(s)To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.
Hypothesis: A booster dose of the naked (i.e. non-adjuvanted) 5x concentrated AKS-452X vaccine, will provide an enhanced immune response after vaccination with any of the registered vaccines, either as primary vaccin or booster vaccin, against COVID…
To compare the efficacy of VRd followed by cilta-cel therapy versus VRd followed by Rd therapy in terms of progression free survival (PFS)